First Liver Cancer Patient Dosed in the MIV-818 Phase Ib Study
- Tuesday, March 10, 2020, 7:13
- PR Newswire
- Add a comment
STOCKHOLM, March 10, 2020 /PRNewswire/ — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient with advanced liver cancer has been dosed in the phase Ib study of MIV-818. The MIV-818 phase I study (NCT03781934) consists of two parts: (i) the already completed phase…
About the Author
admin has written 21839 stories on this site.